ACADIA Pharmaceuticals Inc.  

(Public, NASDAQ:ACAD)   Watch this stock  
Find more results for ACAD
+0.06 (0.15%)
Feb 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 38.56 - 39.32
52 week 17.02 - 42.49
Open 39.03
Vol / Avg. 1.67M/2.34M
Mkt cap 4.76B
P/E     -
Div/yield     -
EPS -2.14
Shares 121.11M
Beta 3.94
Inst. own 102%
Feb 27, 2017
Q4 2016 ACADIA Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Jan 10, 2017
ACADIA Pharmaceuticals Inc at JPMorgan Healthcare Conference
Dec 20, 2016
ACADIA Pharmaceuticals Conference Call to Discuss Top-Line Results From Phase II Study With Pimavanserin for AD Psychosis
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -1359.40% -269578.70%
Operating margin -1374.32% -269855.80%
EBITD margin - -268795.10%
Return on average assets -54.43% -60.09%
Return on average equity -58.21% -64.58%
Employees 340 -
CDP Score - -


3611 Valley Centre Dr Ste 300
SAN DIEGO, CA 92130-3331
United States - Map
+1-858-5582871 (Phone)
+1-858-5582872 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system disorders. The Company's lead drug candidate, NUPLAZID (pimavanserin), is under development for the treatment of Parkinson's disease psychosis (PDP). NUPLAZID is a selective serotonin inverse agonist (SSIA), targeting 5-HT2A receptors. The Company's Pimavanserin is a chemical entity, which has completed Phase III development, and is indicated for the treatment of Parkinson's disease psychosis. NUPLAZID (pimavanserin) is a selective serotonin inverse agonist preferentially targeting the 5-HT2A receptor, a key serotonin receptor that plays a role in psychosis. Through this mechanism, NUPLAZID has demonstrated efficacy in Parkinson's disease psychosis in its Phase III pivotal trial and avoids the side effects of existing antipsychotics.

Officers and directors

Stephen R. Biggar M.D. Ph.D. Chairman of the Board
Age: 45
Bio & Compensation  - Reuters
Stephen R. Davis President, Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Todd S Young Chief Financial Officer, Executive Vice President, Principal Financial Officer and Principal Accounting Officer
Age: 44
Bio & Compensation  - Reuters
Glenn F. Baity Executive Vice President, General Counsel, Secretary
Age: 46
Bio & Compensation  - Reuters
Terrence O. Moore Executive Vice President, Chief Commercial Officer
Age: 61
Bio & Compensation  - Reuters
Srdjan Stankovic M.D. Executive Vice President, Head - Research and Development
Age: 59
Bio & Compensation  - Reuters
Julian C. Baker Director
Age: 50
Bio & Compensation  - Reuters
James M. Daly Director
Bio & Compensation  - Reuters
Edmund P. Harrigan M.D. Director
Age: 63
Bio & Compensation  - Reuters
Laura A. Brege Independent Director
Age: 58
Bio & Compensation  - Reuters